Global Clinical Trials

DAC is building a global network of clinical trial sites and a supporting technology platform to reduce the cost and time of bringing new treatments to market.

 

The Challenge

Innovation in drug development can be dramatically accelerated with faster, less costly clinical trials.

Today, trials for Alzheimer’s treatments take years of effort from researchers, trial participants and care partners, as well as immense biopharmaceutical investments, but face one of the highest failure rates in clinical development. Coordination between trial sites is limited, inhibiting quality data collection and efficiency. Research is largely confined to North America, Europe and Japan, leaving out huge segments of the global population.

Our Approach

DAC is creating a global network of trial sites and a standing, trial-ready platform to support it.

We are linking 90 trial sites in North America with over a dozen in Europe, while surveying site capacity to extend future trials across the rest of the world. This will allow researchers to accelerate patient recruitment and enrollment, enhance trial quality and use advanced analytics to generate scientific insights from a robust database.

Building a clinical trial support network in Europe.

Our Progress & Goals

  • Network

    Developed a network of more than 15 European sites organized for accelerating studies and implementing novel trial designs

  • Opportunity

    Evaluated sites globally and identified opportunities in Africa, South Korea, Singapore, Australia, Japan and China

  • Prepare Sites

    Prepared 30 sites in the European Network

 

“Implementing novel targets in the right clinical trials and having readouts that can be deployed globally is critical and will move the field forward greatly.”

・ Husseini Manji ・

 

Global Head, Science for Minds, Johnson & Johnson